Home » Authors » Kim Coghill

Articles by Kim Coghill

Favrille's Series C Raises $44M For FavId Pivotal Phase III Trial

April 8, 2004

ViaCell Again Considering IPO, Now Anticipating $92M Offering

April 8, 2004

ViaCell Again Considering IPO, Now Anticipating $92M Offering

April 8, 2004

Favrille's Series C Raises $44M For FavId Pivotal Phase III Trial

April 8, 2004

NPS Begins Teduglutide Pivotal Trial In Short-Bowel Syndrome

April 7, 2004

NPS Pharmaceuticals Inc. initiated a pivotal Phase III study for the orphan product teduglutide, a potential treatment for short-bowel syndrome. (BioWorld Today)

With $50M Series B, Archemix Has Funding To Last Until 2007

April 7, 2004

NPS Begins Teduglutide Pivotal Trial In Short-Bowel Syndrome

April 7, 2004

NPS Pharmaceuticals Inc. initiated a pivotal Phase III study for the orphan product teduglutide, a potential treatment for short-bowel syndrome. (BioWorld Today)

With $50M Series B, Archemix Has Funding To Last Until 2007

April 7, 2004

TKT Rebound Continues With Return Of EU Dynepo Rights

April 6, 2004

TKT Rebound Continues With Return Of EU Dynepo Rights

April 6, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...